Krouzon Pharmaceuticals, Inc.
Krouzon Pharmaceuticals, Inc. is developing a first-in-class treatment for ultra-rare orphan pediatric skeletal disorders. Krouzon Pharmaceuticals, Inc. Team: Jacob V. P. Eswarakumar
Read MoreDeMay Bio
DeMay Bio is developing a biologic drug for Rheumatoid Arthritis that leverages a natural human protein to target a novel, but validated, disease mechanism directly in the joints. The new…
Read MoreELIV5
ELIV5 Therapeutics aims to develop a new class of antifungal drugs that target a critical step in fungal metabolism required for pathogen survival and virulence. ELIV5 Team: Choukri Ben…
Read MoreBow Therapeutics
Bow Therapeutics is developing isolation of human monoclonal antibodies against Chikungunya Virus Glycoprotein using Single B-cell sorting Technology. Bow Therapeutics Team: George Georgiev Jose Quiroz
Read MoreBioSapien
Biodegradable active pharmaceutical ingredients encapsulated into a surgical mesh which provides long-term slow release (1 month to 5 years). BioSapien Team: Furwa Hussain Khatija Ali
Read MoreHalo Mountain
Halo Mountain’s drug has the potential to stop Alzheimer’s disease by fighting inflammation and oxidative stress. Halo Mountain Team: Eleanor Haglund
Read MoreVessel Scientific
Our technology is a therapeutic strategy to treat acute myeloid leukemia that works by disrupting cancer metabolism and proliferation. Vessel Scientific Team: Chichao Chen Lingbo Zhang
Read MoreCapCell Biologics
CapCell Biologics is treating rare diseases with implants composed of engineered cells in a protective mesh capsule. CapCell Biologics Team: Ben Young Jon Zaikowski
Read MoreParkside Scientific
New York City based Parkside Scientific develops novel “best-in-class” small molecule drugs that target bromodomain (BrD) proteins for epigenetic control of gene transcription in cancers and inflammatory disorders. Parkside…
Read MoreEpiBone, Inc.
We grow personalized living bone grafts in our lab, from patients own cells in the size and shape they need. EpiBone Team: Nina Tandon EpiBone has been with The Next…
Read More